Euclidean Capital’s Oric Pharmaceuticals ORIC Stock Holding History

Euclidean Capital’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.5M	Hold	989,410	–	–	3.2%	4
2025 Q4	$8.09M	Hold	989,410	–	–	2.19%	5
2025 Q3	$11.9M	Hold	989,410	–	–	4.99%	3
2025 Q2	$10M	Hold	989,410	–	–	3.28%	3
2025 Q1	$5.52M	Hold	989,410	–	–	2.07%	4
2024 Q4	$7.98M	Hold	989,410	–	–	1.08%	4
2024 Q3	$10.1M	Hold	989,410	–	–	1.12%	5
2024 Q2	$7M	Hold	989,410	–	–	0.88%	4
2024 Q1	$13.6M	Hold	989,410	–	–	1.74%	4
2023 Q4	$9.1M	Hold	989,410	–	–	1.02%	8
2023 Q3	$5.99M	Buy	989,410 +241,860	+32%	+$1.98M	1.31%	9
2023 Q2	$5.8M	Hold	747,550	–	–	1.49%	9
2023 Q1	$4.26M	Hold	747,550	–	–	3.74%	7
2022 Q4	$4.4M	Hold	747,550	–	–	4.12%	7
2022 Q3	$2.39M	Hold	747,550	–	–	2.22%	9
2022 Q2	$3.35M	Hold	747,550	–	–	2.85%	9
2022 Q1	$3.99M	Hold	747,550	–	–	2.32%	10
2021 Q4	$11M	Sell	747,550 -29,643	-4%	-$462K	6.25%	7
2021 Q3	$16.3M	Sell	777,193 -219,541	-22%	-$4.45M	7.9%	7
2021 Q2	$17.6M	Hold	996,734	–	–	5.72%	7
2021 Q1	$24.4M	Sell	996,734 -403,701	-29%	-$12.8M	8.17%	3
2020 Q4	$47.4M	Buy	+1,400,435	New	+$40.2M	10.04%	3

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Euclidean Capital's ORIC Position: Q1 2026 in Review

Euclidean Capital held its Oric Pharmaceuticals (ORIC) position steady in Q1 2026 at 989,410 shares worth $12.5M. The position accounts for 3.2% of the portfolio, ranked #4.

Euclidean Capital first reported a position in ORIC in Q4 2020 and has held it in 22 quarters since. The position peaked at $47.4M in Q4 2020. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

Euclidean Capital held 989,410 shares of Oric Pharmaceuticals worth $12.5M as of Q1 2026.
Euclidean Capital left its Oric Pharmaceuticals share count unchanged in Q1 2026.
Oric Pharmaceuticals made up 3.2% of Euclidean Capital's portfolio in Q1 2026, its #4 holding.
Euclidean Capital first reported a position in Oric Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
Euclidean Capital's Oric Pharmaceuticals position peaked at $47.4M in Q4 2020.
182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Euclidean Capital's 13F filing for Q1 2026, filed 15 May 2026.